What is the significance of the FDA approval of PD-1 inhibitors for tumors with MSI? What other canonical driver mutations -- BRAF, ALK, and others -- of similar significance are coming?

What is the significance of the FDA approval of PD-1 inhibitors for tumors with MSI? What other canonical driver mutations -- BRAF, ALK, and others -- of similar significance are coming?

What do you see as the significance of the FDA approval of PD-1 inhibitors for all tumors with MSI? What other canonical driver mutations — BRAF, ALK, and others — of similar significance do you see coming down the road?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Prof. Jean-Yves Blay, MD, PhD

Prof. Jean-Yves Blay, MD, PhD

Professor of Medicine
Université Claude Bernard
Lyon, France
Scientific Director
Canceropole Lyon Rhône Alpes